A new once-a-week obesity jab helps people shed large amounts of body fat, analysis suggests.
Tirzepatide, from Eli Lilly and Company and sold under the brand name Mounjaro, is currently approved by UK regulators for type 2 diabetes but may also soon be approved for obesity.
The National Institute for Health and Care Excellence (Nice) is seeing whether the drug would be a good use of NHS funds before recommending or rejecting it for use across the health service.
